Pesticides & Agrochemicals · Founded 1985 · www.upl-ltd.com · BSE 512070 · NSE UPL · ISIN INE628A01036
No Notes Added Yet
Business
UPL Ltd. is a global provider of sustainable agriculture solutions. The company develops, manufactures, and markets a comprehensive portfolio of crop protection products, including herbicides, insecticides, fungicides, and plant growth regulators. Beyond conventional agrochemicals, UPL has a significant and growing presence in bio-solutions (bio-stimulants, bio-fungicides, bio-insecticides), seed treatment, and post-harvest solutions. Its core business model involves R&D for product development and formulation, manufacturing of active ingredients and formulations, and a vast global distribution network to deliver these solutions directly or indirectly to farmers worldwide. UPL makes money by selling these agricultural inputs, which help farmers enhance crop yield, quality, and resilience against pests and diseases.
Revenue Mix
UPL's revenue is primarily derived from its comprehensive portfolio of agricultural solutions. While it doesn't typically report distinct "segments" in the traditional sense, its business can be broadly categorized by product types and geographical regions:
Product Categories: Crop protection products (herbicides, fungicides, insecticides) form the largest part of the revenue. Bio-solutions are a rapidly growing segment. Other contributions come from seed treatment and post-harvest products.
Geographical Mix: UPL has a significant global presence. Its major markets include Latin America, North America, Europe, India, and the Rest of the World (including Africa, APAC). The company often highlights its diversified geographical exposure as a key strength.
Industry
The Pesticides & Agrochemicals industry is essential for global food security, driven by increasing population and demand for higher agricultural output. It is characterized by intense R&D, stringent regulatory hurdles, and susceptibility to weather patterns and commodity prices. The industry features a few large, integrated players (e.g., Bayer, Syngenta, BASF, Corteva) focused on patented molecules and seeds, and a fragmented landscape of generic/post-patent manufacturers.
UPL is one of the largest global agrochemical companies, positioning itself as a leader in "OpenAg" – an open innovation ecosystem. It has strategically grown through acquisitions (notably Arysta LifeScience) to become a significant player in the post-patent segment and a prominent force in the emerging bio-solutions market. UPL differentiates itself by offering a broad, diverse portfolio, robust supply chain, and global market access, often providing a "full basket" of solutions to farmers.
MOAT
Global Scale & Distribution Network: UPL operates in over 130 countries, possessing one of the most extensive global distribution and sales networks in the industry. This scale allows for significant market reach and cost efficiencies.
Broad Product Portfolio: A wide array of crop protection products (conventional and bio-solutions) catering to diverse crops and regional needs provides resilience against product-specific challenges and allows for cross-selling.
Backward Integration: Partial backward integration into manufacturing key active ingredients provides some cost control, supply chain stability, and quality assurance.
Regulatory Expertise: Navigating the complex and evolving global regulatory landscape for agrochemicals is a high barrier to entry. UPL's extensive experience and product registrations are a significant asset.
Innovation in Formulations & Bio-solutions: While not a primary discoverer of new molecules, UPL excels in developing new formulations, combinations, and application methods for existing active ingredients, as well as being a front-runner in the rapidly growing bio-solutions space.
Growth Drivers
Growing Global Food Demand: Increasing world population and changing dietary habits necessitate higher agricultural productivity and protection against crop losses.
Expansion of Bio-solutions Market: Increasing farmer and consumer preference for sustainable, eco-friendly agricultural practices drives demand for UPL's bio-solutions portfolio.
Geographical Expansion & Market Penetration: Deeper penetration in existing markets and strategic expansion into underserved regions.
Product Innovation: Continuous introduction of new formulations, integrated pest management solutions, and specialized products tailored to regional agricultural needs.
Synergies from Acquisitions: Realizing cost and revenue synergies from past acquisitions (e.g., Arysta LifeScience integration) to improve profitability and market share.
Digital Agriculture Adoption: Potential for growth through digital platforms that enhance product recommendations and farm management.
Risks
Regulatory Environment: Strict environmental regulations, bans on certain active ingredients (e.g., glyphosate, chlorpyrifos), and evolving registration processes can significantly impact product sales and increase R&D costs.
Weather Dependency & Crop Cycles: Agricultural demand is inherently tied to weather patterns, which can impact crop yields, farmer income, and their spending on inputs.
Commodity Price Volatility: Fluctuations in agricultural commodity prices directly affect farmer profitability and their purchasing power for agrochemicals.
Input Cost Volatility: Prices of raw materials (often petrochemical-derived) and energy can fluctuate significantly, impacting manufacturing costs and profit margins.
Currency Fluctuations: Extensive global operations expose UPL to significant currency risks, affecting reported revenues and profits.
Competition: Intense competition from both large multinational players and numerous generic manufacturers can lead to pricing pressure.
Debt Levels: Significant acquisitions have increased debt, requiring careful management of leverage and interest expenses.
Litigation & Environmental Concerns: Potential for lawsuits related to product safety, environmental impact, or competition.
Management & Ownership
UPL Ltd. is promoted by the Shroff family, with Mr. Rajnikant Shroff as the Founder Chairman and Mr. Jai Shroff as the Global CEO. The promoter group holds a significant stake in the company. Management is generally perceived as entrepreneurial and aggressive, particularly in its growth strategy through inorganic expansion (M&A). The company has a diverse board of directors. Ownership structure includes the promoter group, domestic institutional investors, foreign institutional investors, and public shareholders, typical for a large Indian listed company.
Outlook
UPL operates in a fundamental industry driven by long-term global food demand. The company's comprehensive portfolio, global distribution, and growing focus on sustainable solutions (bio-solutions) position it to capture market opportunities. The successful integration of past acquisitions and realization of planned synergies are crucial for margin expansion and debt reduction. However, the business faces inherent risks from stringent and evolving regulations on agrochemicals, volatile agricultural cycles, and commodity prices. Managing its debt levels effectively while continuing to innovate and expand its sustainable offerings will be key to its performance. The increasing global focus on sustainable agriculture also presents both an opportunity for its bio-solutions segment and a challenge for its conventional chemical portfolio, requiring constant adaptation and R&D.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 9887 | 14078 | 9067 | 11090 | 10907 | 15573 | 9216 | 12019 | 12269 | 18335 |
| Other Income | 151 | 126 | 98 | 111 | 170 | 107 | 143 | 250 | 92 | 178 |
| Total Income | 10038 | 14204 | 9165 | 11201 | 11077 | 15680 | 9359 | 12269 | 12361 | 18513 |
| Total Expenditure | 9794 | 12230 | 7966 | 9738 | 8951 | 12382 | 7820 | 10018 | 9952 | 14777 |
| Operating Profit | 244 | 1974 | 1199 | 1463 | 2126 | 3298 | 1539 | 2251 | 2409 | 3736 |
| Interest | 1191 | 1090 | 913 | 1070 | 730 | 914 | 1007 | 784 | 774 | 836 |
| Depreciation | 676 | 794 | 660 | 697 | 688 | 705 | 731 | 771 | 827 | 915 |
| Exceptional Income / Expenses | -17 | -105 | -49 | -8 | -76 | -275 | -9 | 142 | -56 | -16 |
| Profit Before Tax | -1640 | -15 | -423 | -312 | 632 | 1404 | -208 | 838 | 752 | 1969 |
| Provision for Tax | -59 | 110 | 72 | 138 | -499 | 298 | -14 | 172 | 181 | 598 |
| Profit After Tax | -1581 | -125 | -495 | -450 | 1131 | 1106 | -194 | 666 | 571 | 1371 |
| Adjustments | 364 | 165 | 111 | 7 | -303 | -210 | 106 | -113 | -175 | -310 |
| Profit After Adjustments | -1217 | 40 | -384 | -443 | 828 | 896 | -88 | 553 | 396 | 1061 |
| Adjusted Earnings Per Share | -15.6 | 0.5 | -4.9 | -5.7 | 10.7 | 11.3 | -1.1 | 6.5 | 4.7 | 12.6 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 12091 | 14048 | 16312 | 17378 | 21837 | 35756 | 38694 | 46240 | 53576 | 43098 | 46637 | 51839 |
| Other Income | 206 | 316 | 495 | 429 | 332 | 266 | 259 | 296 | 477 | 483 | 486 | 663 |
| Total Income | 12296 | 14364 | 16807 | 17807 | 22169 | 36022 | 38953 | 46536 | 54053 | 43581 | 47123 | 52502 |
| Total Expenditure | 9827 | 11653 | 13331 | 13880 | 18080 | 28983 | 30343 | 36726 | 43380 | 38559 | 39037 | 42567 |
| Operating Profit | 2470 | 2711 | 3476 | 3927 | 4089 | 7039 | 8610 | 9810 | 10673 | 5022 | 8086 | 9935 |
| Interest | 632 | 704 | 782 | 791 | 998 | 1643 | 2060 | 2295 | 2963 | 3852 | 3627 | 3401 |
| Depreciation | 425 | 676 | 672 | 675 | 881 | 2012 | 2173 | 2359 | 2547 | 2763 | 2750 | 3244 |
| Exceptional Income / Expenses | -3 | -129 | -81 | -63 | -451 | -623 | -238 | -324 | -170 | -252 | -408 | 61 |
| Profit Before Tax | 1410 | 1117 | 1922 | 2305 | 1773 | 2764 | 4181 | 4966 | 5150 | -2087 | 829 | 3351 |
| Provision for Tax | 244 | 165 | 189 | 275 | 198 | 586 | 686 | 529 | 736 | -209 | 9 | 937 |
| Profit After Tax | 1166 | 952 | 1733 | 2030 | 1575 | 2178 | 3495 | 4437 | 4414 | -1878 | 820 | 2414 |
| Adjustments | -22 | -12 | -6 | -8 | -84 | -402 | -624 | -811 | -844 | 678 | 77 | -492 |
| Profit After Adjustments | 1144 | 940 | 1727 | 2022 | 1491 | 1776 | 2871 | 3626 | 3570 | -1200 | 897 | 1922 |
| Adjusted Earnings Per Share | 17.1 | 14 | 21.8 | 25.4 | 18.7 | 22.3 | 36 | 45.5 | 45.7 | -15.3 | 11.3 | 22.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 8% | 0% | 5% | 14% |
| Operating Profit CAGR | 61% | -6% | 3% | 13% |
| PAT CAGR | 0% | -43% | -18% | -3% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 1% | -0% | -4% | 5% |
| ROE Average | 3% | 5% | 11% | 17% |
| ROCE Average | 8% | 9% | 11% | 14% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 5860 | 5889 | 7397 | 9169 | 14715 | 19283 | 20887 | 21675 | 26858 | 24807 | 29213 |
| Minority's Interest | 44 | 44 | 33 | 19 | 3454 | 3312 | 3693 | 4647 | 8571 | 7899 | 8613 |
| Borrowings | 1694 | 2266 | 5350 | 5873 | 26382 | 27371 | 22141 | 24591 | 20144 | 24010 | 18263 |
| Other Non-Current Liabilities | 692 | 112 | -97 | -189 | 1622 | 1779 | 2417 | 1714 | 1306 | 374 | 22 |
| Total Current Liabilities | 5993 | 8168 | 7028 | 7642 | 16262 | 16685 | 19627 | 27976 | 29037 | 26861 | 28569 |
| Total Liabilities | 14284 | 16479 | 19711 | 22514 | 62435 | 68430 | 68765 | 80603 | 85916 | 83951 | 84680 |
| Fixed Assets | 4031 | 3862 | 4071 | 4437 | 32149 | 35322 | 34765 | 36193 | 38713 | 39056 | 39084 |
| Other Non-Current Assets | 1765 | 1410 | 1942 | 3053 | 3564 | 3866 | 3930 | 4682 | 5175 | 5567 | 5935 |
| Total Current Assets | 8489 | 11183 | 13658 | 15004 | 26696 | 29191 | 30015 | 39680 | 41988 | 39299 | 39617 |
| Total Assets | 14284 | 16479 | 19711 | 22514 | 62435 | 68430 | 68765 | 80603 | 85916 | 83951 | 84680 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 1018 | 1046 | 1177 | 2877 | 2859 | 2826 | 6724 | 4797 | 5797 | 5967 | 5943 |
| Cash Flow from Operating Activities | 1409 | 1396 | 2585 | 2839 | 2356 | 8739 | 7212 | 6496 | 7751 | 2321 | 10151 |
| Cash Flow from Investing Activities | -331 | -1719 | -999 | -2093 | -30920 | -2643 | -2101 | -3819 | -1490 | -2478 | -1840 |
| Cash Flow from Financing Activities | -991 | 469 | 140 | -801 | 28894 | -2175 | -6713 | -1921 | -6227 | 164 | -4793 |
| Net Cash Inflow / Outflow | 86 | 146 | 1726 | -55 | 330 | 3921 | -1602 | 756 | 34 | 7 | 3518 |
| Closing Cash & Cash Equivalent | 973 | 1177 | 2880 | 2859 | 2827 | 6724 | 4797 | 5797 | 5967 | 5943 | 9478 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 17.07 | 13.98 | 21.83 | 25.35 | 18.69 | 22.27 | 36 | 45.46 | 45.66 | -15.35 | 11.28 |
| CEPS(Rs) | 23.74 | 24.21 | 30.45 | 33.92 | 30.79 | 52.54 | 71.07 | 85.21 | 89.02 | 11.32 | 44.91 |
| DPS(Rs) | 3.21 | 3.21 | 4.49 | 5.13 | 5.13 | 5.77 | 9.62 | 9.62 | 9.62 | 0.96 | 6 |
| Book NAV/Share(Rs) | 87.43 | 31.08 | 92.6 | 114.96 | 184.5 | 204.34 | 224.44 | 271.52 | 343.23 | 317 | 367.46 |
| Core EBITDA Margin(%) | 18.72 | 16.7 | 17.87 | 16.41 | 14.58 | 16.15 | 18.32 | 17.38 | 15.82 | 8.54 | 13.5 |
| EBIT Margin(%) | 16.89 | 12.7 | 16.21 | 14.53 | 10.75 | 10.51 | 13.69 | 13.26 | 12.59 | 3.32 | 7.92 |
| Pre Tax Margin(%) | 11.67 | 7.79 | 11.52 | 10.82 | 6.88 | 6.59 | 9.17 | 9.07 | 7.99 | -3.93 | 1.47 |
| PAT Margin (%) | 9.65 | 6.64 | 10.39 | 9.53 | 6.11 | 5.19 | 7.67 | 8.1 | 6.85 | -3.53 | 1.46 |
| Cash Profit Margin (%) | 13.16 | 11.35 | 14.42 | 12.69 | 9.53 | 9.99 | 12.43 | 12.41 | 10.8 | 1.66 | 6.34 |
| ROA(%) | 8.63 | 6.19 | 9.58 | 9.62 | 3.71 | 3.33 | 5.09 | 5.94 | 5.3 | -2.21 | 0.97 |
| ROE(%) | 21 | 23.95 | 36.86 | 24.63 | 13.19 | 14.05 | 20.44 | 22.43 | 18.2 | -7.28 | 3.04 |
| ROCE(%) | 23.03 | 17.95 | 21.71 | 20.94 | 9.29 | 9.6 | 13.47 | 15.26 | 16.16 | 3.43 | 8.42 |
| Receivable days | 105.68 | 113.15 | 117.68 | 100.3 | 125.56 | 102.45 | 96.14 | 91.58 | 95 | 118.71 | 103.28 |
| Inventory Days | 81.78 | 85.56 | 86.91 | 74.46 | 96.79 | 73.9 | 69.15 | 75 | 76.63 | 91.88 | 74.86 |
| Payable days | 179.08 | 192.89 | 206.15 | 237.35 | 259.79 | 195.52 | 219.73 | 242.35 | 228.56 | 248.1 | 228.53 |
| PER(x) | 16.57 | 21.85 | 21.26 | 18.36 | 32.7 | 14.06 | 17.11 | 16.24 | 15.07 | 0 | 56.39 |
| Price/Book(x) | 3.23 | 9.83 | 5.01 | 4.05 | 3.31 | 1.53 | 2.74 | 2.72 | 2 | 1.38 | 1.73 |
| Dividend Yield(%) | 1.13 | 1.05 | 0.96 | 1.1 | 0.84 | 1.84 | 1.56 | 1.3 | 1.39 | 0.22 | 0.94 |
| EV/Net Sales(x) | 1.76 | 1.75 | 2.46 | 2.35 | 3.44 | 1.31 | 1.76 | 1.77 | 1.32 | 1.31 | 1.38 |
| EV/Core EBITDA(x) | 8.59 | 9.08 | 11.57 | 10.41 | 18.35 | 6.67 | 7.9 | 8.32 | 6.63 | 11.23 | 7.99 |
| Net Sales Growth(%) | 12.25 | 16.19 | 16.12 | 6.54 | 25.66 | 63.74 | 8.22 | 19.5 | 15.87 | -19.56 | 8.21 |
| EBIT Growth(%) | 20.56 | -10.83 | 48.49 | 14.5 | -10.5 | 59.04 | 41.62 | 16.34 | 11.73 | -78.24 | 152.46 |
| PAT Growth(%) | 24.76 | -18.38 | 82.04 | 17.14 | -22.41 | 38.29 | 60.47 | 26.95 | -0.52 | -142.55 | 143.66 |
| EPS Growth(%) | 20.45 | -18.1 | 56.17 | 16.14 | -26.26 | 19.11 | 61.66 | 26.3 | 0.42 | -133.61 | 173.52 |
| Debt/Equity(x) | 0.56 | 2.52 | 0.86 | 0.72 | 1.98 | 1.49 | 1.14 | 1.33 | 0.86 | 1.14 | 0.81 |
| Current Ratio(x) | 1.42 | 1.37 | 1.94 | 1.96 | 1.64 | 1.75 | 1.53 | 1.42 | 1.45 | 1.46 | 1.39 |
| Quick Ratio(x) | 0.93 | 0.91 | 1.35 | 1.37 | 1.08 | 1.28 | 1.05 | 0.95 | 0.96 | 0.99 | 1.03 |
| Interest Cover(x) | 3.23 | 2.59 | 3.46 | 3.91 | 2.78 | 2.68 | 3.03 | 3.16 | 2.74 | 0.46 | 1.23 |
| Total Debt/Mcap(x) | 0.17 | 0.26 | 0.17 | 0.18 | 0.6 | 1.15 | 0.48 | 0.49 | 0.43 | 0.83 | 0.44 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 32.52 | 32.52 | 32.52 | 32.52 | 33.5 | 33.5 | 33.5 | 33.5 | 33.5 | 33.51 |
| FII | 34.38 | 33.64 | 34.51 | 34.22 | 32.52 | 34.22 | 34.9 | 37.01 | 38.84 | 41.78 |
| DII | 16.82 | 15.32 | 15.74 | 17.65 | 18.71 | 18.36 | 18.1 | 17.16 | 16.73 | 14.65 |
| Public | 12.97 | 15.21 | 13.92 | 12.3 | 12.33 | 10.92 | 10.58 | 9.45 | 8.78 | 8.74 |
| Others | 3.31 | 3.31 | 3.31 | 3.32 | 2.94 | 3 | 2.93 | 2.87 | 2.15 | 1.32 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 24.41 | 24.41 | 24.41 | 24.41 | 28.29 | 28.29 | 28.29 | 28.29 | 28.29 | 28.29 |
| FII | 25.81 | 25.25 | 25.91 | 25.69 | 27.46 | 28.89 | 29.47 | 31.25 | 32.8 | 35.27 |
| DII | 12.62 | 11.5 | 11.81 | 13.25 | 15.79 | 15.5 | 15.28 | 14.49 | 14.13 | 12.36 |
| Public | 9.74 | 11.42 | 10.45 | 9.23 | 10.41 | 9.22 | 8.93 | 7.98 | 7.42 | 7.38 |
| Others | 2.48 | 2.49 | 2.48 | 2.49 | 2.48 | 2.53 | 2.47 | 2.43 | 1.81 | 1.11 |
| Total | 75.06 | 75.06 | 75.06 | 75.06 | 84.44 | 84.44 | 84.44 | 84.44 | 84.44 | 84.42 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +8% | 0% | +5% | +14% |
| Operating Profit CAGR | +61% | -6% | +3% | +13% |
| PAT CAGR | — | -43% | -18% | -3% |
| Share Price CAGR | +1% | 0% | -4% | +5% |
| ROE Average | +3% | +5% | +11% | +17% |
| ROCE Average | +8% | +9% | +11% | +14% |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 32.52 | 32.52 | 32.52 | 32.52 | 33.5 | 33.5 | 33.5 | 33.5 | 33.5 | 33.51 |
| FII | 34.38 | 33.64 | 34.51 | 34.22 | 32.52 | 34.22 | 34.9 | 37.01 | 38.84 | 41.78 |
| DII | 16.82 | 15.32 | 15.74 | 17.65 | 18.71 | 18.36 | 18.1 | 17.16 | 16.73 | 14.65 |
| Public | 64.17 | 64.17 | 64.17 | 64.16 | 63.55 | 63.5 | 63.57 | 63.62 | 64.35 | 65.17 |
| Others | 3.31 | 3.31 | 3.31 | 3.32 | 2.94 | 3 | 2.93 | 2.87 | 2.15 | 1.32 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 24.41 | 24.41 | 24.41 | 24.41 | 28.29 | 28.29 | 28.29 | 28.29 | 28.29 | 28.29 |
| FII | 25.81 | 25.25 | 25.91 | 25.69 | 27.46 | 28.89 | 29.47 | 31.25 | 32.8 | 35.27 |
| DII | 12.62 | 11.5 | 11.81 | 13.25 | 15.79 | 15.5 | 15.28 | 14.49 | 14.13 | 12.36 |
| Public | 48.17 | 48.17 | 48.17 | 48.16 | 53.66 | 53.62 | 53.68 | 53.73 | 54.34 | 55.01 |
| Others | 2.48 | 2.49 | 2.48 | 2.49 | 2.48 | 2.53 | 2.47 | 2.43 | 1.81 | 1.11 |
| Total | 75.06 | 75.06 | 75.06 | 75.06 | 84.44 | 84.44 | 84.44 | 84.44 | 84.44 | 84.42 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.